surmount-1 trial tirzepatide weight loss nondiabetic SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, Gastrointestinal tolerability and weight reduction

Pharmacological interventions, particularly Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs), including Liraglutide and Semaglutide have emerged as a significant treatment option

Exercise-inducible circulating extracellular vesicle irisin promotes browning and the thermogenic program in white adipose tissue

This is sometimes called vasomotor rhinitis. Another possibility is that the medication is worsening silent reflux or GERD (gastroesophageal reflux disease)

"RFK Jr

Acute and sustained GLP-1 receptor signalling leads to reduction in appetite and food intake leading to subsequent weight loss [14, 15]

Melatonin protects blood-brain barrier integrity and permeability by inhibiting matrix metalloproteinase-9 via the NOTCH3/NF-B pathway